Study of Olutasidenib and Temozolomide in HGG
Trial details
- Registry ID
- NCT06161974
- Phase
- Phase 2
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Olutasidenib and Temozolomide in HGGNCT06161974 | Rigel Pharmaceuticals | Phase 2 | Recruiting | 2029-06Estimated |
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |